Aldurazyme (laronidase) - prescribing information
U.S. Food and Drug Administration
U.S. prescribing information for laronidase, dosed 0.58 mg/kg IV once weekly for MPS I.
Open sourceNew gait deterioration, weakness or bladder dysfunction - suspect spinal cord compression. Stridor at rest, escalating work of breathing or new desaturation - urgent airway and respiratory assessment. A potentially difficult airway and cervical cord risk before any sedation or surgery. Normal total urinary GAGs do not exclude MPS IVA - continue subtype-specific enzyme testing when the phenotype is convincing.
U.S. Food and Drug Administration
U.S. prescribing information for laronidase, dosed 0.58 mg/kg IV once weekly for MPS I.
Open sourceU.S. Food and Drug Administration
U.S. prescribing information for galsulfase, dosed 1 mg/kg IV once weekly for MPS VI.
Open sourceU.S. Food and Drug Administration
U.S. prescribing information for Fayuvi gene therapy, FDA-approved for neurologic manifestations of MPS IIIA with preserved neurodevelopmental function.
Open sourceU.S. Food and Drug Administration
U.S. prescribing information for vestronidase alfa, dosed 4 mg/kg IV every 2 weeks for MPS VII.
Open sourcePediatric metabolics / MPS clinical guide · 2026
A pediatric clinical guide to the mucopolysaccharidoses: recognition of the clinical pattern, biochemical and molecular testing, subtype-specific therapy, and surveillance and perioperative planning.
Open sourceU.S. Food and Drug Administration · 2026
U.S. prescribing information for tividenofusp alfa-eknm, an accelerated-approval enzyme replacement for the neurologic manifestations of MPS II.
Open sourceGeneReviews, University of Washington · 2024
The Sanfilippo syndromes (MPS IIIA-D): progressive neurocognitive decline with mild somatic features, diagnosis and supportive management.
Open sourceGeneReviews, University of Washington · 2024
Morquio A syndrome: skeletal disease, the role of urinary GAGs and enzyme testing, elosulfase alfa therapy and cervical spine surveillance.
Open sourceGeneReviews, University of Washington · 2024
The X-linked Hunter syndrome: clinical features, enzyme and molecular testing, idursulfase therapy and the approach to neuronopathic disease.
Open sourceGeneReviews, University of Washington · 2024
Diagnosis, management and genetic counselling for MPS I, including the severe Hurler spectrum and the role of early haematopoietic stem cell transplantation.
Open sourceNo sources are linked to this topic yet. Browse the full guidelines and literature list.
IV weekly escalation: 3 mg/kg for at least 4 weeks, then 7.5 mg/kg for at least 4 weeks, then 15 mg/kg weekly as maintenance if tolerated. Follow the label for transition from idursulfase.
Monitor: CSF heparan sulfate and neurologic function; infusion-associated reactions.
4 mg/kg IV every 2 weeks.
Monitor: Infusion-associated reactions; clinical response and urinary GAGs as directed.
No medication doses are linked to this topic yet. See the full dose reference.